Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRS 344

Next Previous
Drug Profile

PRS 344

Alternative Names: PDL×4-1BB; PRS-344; PRS-344/ONC0055; PRS-344/S095012; PRS-344S095012; S-095012; S-95012

Latest Information Update: 06 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pieris Pharmaceuticals
  • Developer Palvella Therapeutics; Servier
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Lipocalins; Recombinant fusion proteins
  • Mechanism of Action CD137 antigen agonists; Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 25 Apr 2025 Efficacy and adverse event data from a phase I/II trial in Slod tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 08 Apr 2025 Servier completes phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, Belgium, Australia, USA (IV) (NCT05159388)
  • 13 Dec 2024 Pieris Pharmaceuticals has merged with Palvella Therapeutics to form Palvella Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top